Clinical Trials or Standard Treatment?
Understanding Options for Blood Cancers

Welcome and Introductions

John P. Leonard, MD
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, NY

March 18, 2015
Disclosures

• Consulting
  – Celgene Corporation
  – Genentech, Inc.
  – Gilead Sciences, Inc.
  – Pharmacylics, Inc.
  – Seattle Genetics, Inc.
  – Spectrum Pharmaceuticals, Inc.

How a Drug is Developed for Blood Cancers

• Preclinical rationale – laboratory studies
• Pharmacology and manufacturing
• Animal studies – toxicity and efficacy
• Human studies
  – Phase I
  – Phase II
  – Phase III
  – Phase IV
Blood Cancer Drug Development: Unique Challenges

- Many different diseases
  - Treatment approaches vary from observation to bone marrow transplantation
- Why do we need new treatments?
  - Increase the cure rate
  - Improve survival
  - Minimize toxicity/side effects
- Relatively rare diseases
  - Requires multicenter or even international collaborations
- Many existing agents have significant activity

Cost of developing a drug may exceed several hundred million $.
Increasing interest in “small diseases” as progress can be made.

Phase I Trials

- History
  - First in human
  - Goal: define maximum tolerated dose of potentially active agents
  - PRIMARY ENDPOINT: TOXICITY
  - Generally single-arm studies in patients with refractory disease
  - Often around 20 patients
- Blood cancer issues
  - Uncommon for first-in-human studies to be done in blood cancers
  - “Disease-specific” phase I more common
  - Novel biological agents require new trial designs
    - “Biologically active” dose more appropriate than maximum tolerated dose
  - Primary endpoint: remains toxicity
Phase II Trials

- Very common in oncology
  - May study a variety of doses and schedules
  - Goal: determine activity in disease
  - PRIMARY ENDPOINT: EFFICACY
  - Common to have many correlative scientific studies
  - Often single-arm studies in patients with either newly diagnosed or refractory disease
  - Usually between 20 and 80 patients
- Randomized phase II
  - Becoming more common
  - Necessary when “historical control” group does not exist
  - May explore different agents or combinations to determine optimal regimens for the ultimate phase III trial
  - Primary endpoint: efficacy, but two arms not directly compared

Phase III Trials

- Randomized trials to definitively evaluate efficacy
  - Single dose and schedule, determined by phase II
  - Large (>100 patients) with substantial statistical power
  - PRIMARY ENDPOINT: EFFICACY
  - Very few correlative scientific studies
- Placebo rarely utilized in oncology
  - Standard of care generally is control arm
  - Numerous examples in lymphoma of importance of randomized phase III trials
  - FDA may allow a single-arm trial if there is no clear standard of care (relevant particularly to rare diseases)
Lessons in Blood Cancers From Phase III Trials

• CHOP is the standard for aggressive NHL
  – High priority lymphoma study
  – CHOP vs MACOP-B vs m-BACOD vs ProMACE-CytaBOM
  – Equivalent outcomes except for toxicity

• ABVD is the standard for advanced stage Hodgkin lymphoma

• Abbreviated CHOP with radiation is sufficient for localized aggressive NHL
  – CHOP x 3 + XRT vs CHOP x 8
  – Superior outcomes in combined modality arms

Lessons in Oncology From Phase III Trials

• Role of high-dose chemotherapy and autologous stem cell support in high-risk breast cancer
R-CHOP for DLBCL

Summary of 4 large randomized trials
- R-CHOP produced a statistically and clinically meaningful improvement in remission and survival compared with CHOP
- Benefit seen in all age groups and all risks of NHL. Low-risk patients may experience the most benefit
- No role for “maintenance” rituximab following chemotherapy if R-CHOP is given initially

Recent US Phase III Trials in Lymphoma
- Hodgkin lymphoma
  - ABVD vs Stanford V
- Aggressive lymphoma
  - EPOCH-R vs CHOP-R
  - Early vs late ASCT
- Follicular lymphoma
  - RESORT trial
  - R-CHOP vs CHOP + I-131 tositumomab
  - Idiotype vaccine (placebo)
Phase IV Trials

- “Post-marketing” trials
  - Larger patient groups to determine additional toxicity profile (required by FDA for approval)
  - New indications
  - New schedules
  - New routes of administration

Correlative Laboratory Projects

- Tumor and serum “banks”
  - Growing in importance
  - New regulations require extensive consenting
  - Importance in evaluating “targeted therapy”

As important for the future of blood cancer research as participating in large clinical trials
Who Conducts Clinical Trials?

• Sponsor (organizer)
  – National Cancer Institute
  – Cooperative groups (CALGB/Alliance, SWOG, ECOG)
  – Pharmaceutical companies
  – Groups of academic and treatment centers
  – Individual academic and treatment centers

• Investigator (local center)
  – Academic centers/medical colleges
  – Large hospitals
  – Small hospitals and clinics
  – Small clinical practices

• Virtually all “blood cancer expert” MDs are doing trials

Advantages to Research

• Access to novel agents
• “Cutting-edge” care
• Standardization of staging and follow-up
• Team approach to care
  – Dedicated trials nurse; data manager; other MDs
  – Attention to details
• Altruism
• Reasonable expectations
  – Full understanding of rationale and goals of trial
  – Reassurance that you can leave trial if new information becomes available
  – Results of clinical research
• Patience….
Myths About Clinical Research

- All clinical research is performed at large academic medical centers
- Use of placebo and deviation from standard care
- Clinical research increases the cost of care
- All treatments on clinical trials are free

Cancer Clinical Trials

- Approximately 1–2% of patients overall enroll in clinical trials
- NCI cooperative group clinical trials from 1998–1999
  - 35% of subjects 60 or older
  - 17% of subjects 70 or older
Why Don’t Patients Enroll in Clinical Trials?

• Possibilities
  – Lack of awareness (patient and MD)
  – Nature of treatment
  – Feeling that they are not end stage and don’t need trial
  – Fear of unproven treatments
  – Excluded by comorbid illnesses
  – Complexities of study design and need for procedures
  – Concern about perception of benefit
  – Insufficient financial, logistic, social support
  – Distance
  – MD financial incentives/disincentives

Slow Accrual To Cancer Clinical Trials Causes Patients To Die Unnecessarily

• US national CHOP vs CHOP-R study in DLBCL
  – 600 patients, accrued nationally over 3 years
  – To complete 1 year earlier, would have needed 100 more patients/year nationally
  – Amounts to about 1–2 patients/per center
• 20% improvement in cure rates
  – During 1 year, 20,000 DLBCL pts diagnosed in US
  – Completing study 1 year earlier would have saved estimated 4000 lives

CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP-R, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; DLBCL, diffuse large B-cell lymphoma.
Is a Clinical Trial Right for You?

- Ask your doctor
  - Do they participate?
  - If not, can they refer you to someone who does to discuss?
  - Most blood cancer expert centers are involved
- Reach out
  - LLS (www.LLS.org), other organizations
  - Internet/clinicaltrials.gov
  - Company websites
- Clinical trials should be at least considered for every situation

Clinical Trials or Standard Treatment?
Understanding Options for Blood Cancers

Question & Answer Session

The speaker's slides are available for download at www.LLS.org/programs
Clinical Trials or Standard Treatment?
Understanding Options for Blood Cancers

The Leukemia & Lymphoma Society (LLS) offers:

• Live, weekly Online Chats are moderated by an oncology social worker and provide a friendly forum to share experiences.
  ➢ WEBSITE: www.LLS.org/chat

• Co-Pay Assistance Program offers financial assistance to qualified cancer patients to help with treatment-related expenses and insurance premiums. Patients may apply online or over the phone with a Co-Pay Specialist.
  ➢ WEBSITE: www.LLS.org/copay
  ➢ TOLL-FREE PHONE: (877) LLS-COPAY

• For more information about blood cancers and other LLS programs, please contact an LLS Information Specialist.
  ➢ EMAIL: infocenter@LLS.org
  ➢ TOLL-FREE PHONE: (800) 955-4572